Please try another search
For the three months ended 31 March 2022, SD Biotechnologies Co Ltd revenues decreased 33% to W24.75B. Net loss decreased 21% to W6.87B. Revenues reflect Foreign Countries segment decrease of 38% to W11.68B, South Korea (Country) segment decrease of 28% to W13.07B. Lower net loss reflects Commission Paid decrease of 44% to W3.24B (expense), R & D Expense decrease of 28% to W1.06B (expense).
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 10189.19 | 11813.22 | 15513.57 | |
Gross Profit | 4875.34 | 4142.82 | 2306.12 | |
Operating Income | -1695.32 | -2850.32 | -9380.62 | |
Net Income | -1565.98 | -2915.44 | -2789.92 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 73838.86 | 76122.61 | 100451.02 | 95193.4 |
Total Liabilities | 30442.33 | 31012.94 | 87635.43 | 79778.14 |
Total Equity | 43396.53 | 45109.67 | 12815.59 | 15415.26 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 2364.86 | 7874.77 | -949.54 | |
Cash From Investing Activities | 112.14 | -6553.35 | 974.67 | |
Cash From Financing Activities | -1594.68 | -446.61 | -478.51 | |
Net Change in Cash | 21075.67 | 602.14 | -7955.23 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review